Docoh
Loading...

KDMN Kadmon

GRANT
Utility
Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors
27 Jul 21
This invention provides methods of treating inflammatory conditions and autoimmune diseases in a mammal, comprising administering to the mammalian subject in need thereof a therapeutically effective amount of a compound, or pro-drug thereof, or pharmaceutically acceptable salt or ester of said compound or pro-drug, wherein the compound is an inhibitor of glucose uptake.
Ji-In Kim, Kellen L. Olszewski, Anthony M. Barsotti, Masha V. Poyurovsky, Kevin G. Liu, Koi Morris, Xuemei Yu
Filed: 27 Apr 18
APP
Utility
Inhibitors of Rho Associated Coiled-coil Containing Protein Kinase
3 Jun 21
The invention relates to inhibitors of ROCK1 and/or ROCK2.
Eduardas Skucas, Kevin G. Liu, Ji-In Kim, Masha V. Poyurovsky, Rigen Mo, Jingya Zhang
Filed: 23 Jul 18
APP
Utility
Rho Kinase Inhibitors
20 May 21
The invention relates to inhibitors of ROCK1 and/or ROCK2.
Masha V. Poyurovsky, Ji-In Kim, Kevin G. Liu, Alexandra Zanin-Zhorov
Filed: 26 Jun 20
GRANT
Utility
Glucose uptake inhibitors
27 Apr 21
Kellen L. Olszewski, Ji-In Kim, Masha V. Poyurovsky, Kevin G. Liu, Anthony Barsotti, Koi Morris
Filed: 29 Apr 19
APP
Utility
Immunomodulatory Agents
28 Jan 21
The invention provides antibodies that specifically bind to PD-L1 and fusion molecules comprising PD-L1 binding proteins constructed with an IL 15 receptor-binding domain, nucleic acid molecules encoding the same, and therapeutic compositions thereof.
Samuel D. Waksal, Zhenping Zhu, Yan Wu, Stella A. Martomo, Zhaojing Zhong, Dan Lu
Filed: 9 Mar 20
GRANT
Utility
Stable trientine formulations
28 Dec 20
Provided are pharmaceutical dosage forms comprising (i) trientine or a pharmaceutically acceptable salt of trientine, in a (ii) sealed packaging.
Samuel D. Waksal
Filed: 2 Feb 16
APP
Utility
Human ANTI-VEGFR-2/KDR Antibodies
5 Aug 20
The invention relates to antibodies that bind to VEGFR-2.
Dan Lu, Zhenping Zhu
Filed: 24 Feb 20
GRANT
Utility
Treatment of infectious diseases with glucose uptake inhibitors
3 Aug 20
Kellen Olszewski, Masha Poyurovsky, Anthony Barsotti, Ji-Ln Kim, Kevin G. Liu
Filed: 23 Jun 16
GRANT
Utility
Rho kinase inhibitors
29 Jun 20
The invention relates to inhibitors of ROCK1 and/or ROCK2.
Masha V. Poyurovsky, Ji-In Kim, Kevin G. Liu, Alexandra Zanin-Zhorov
Filed: 17 Jan 19
APP
Utility
Inhibitors of RHO Associated Coiled-Coil Containing Protein Kinase
24 Jun 20
The invention relates to inhibitors of ROCK1 and/or ROCK2.
Eduardas Skucas, Kevin G. Liu, Ji-In Kim, Masha V. Poyurovsky, Rigen Mo
Filed: 12 Jun 18
APP
Utility
Inhibitors of Rho Associated Coiled-coil Containing Protein Kinase
27 May 20
The invention relates to inhibitors of ROCK1 and/or ROCK2.
Eduardas Skucas, Kevin G. Liu, Ji-In Kim, Masha V. Poyurovsky, Rigen Mo, Jingya Zhang
Filed: 22 Jul 18
GRANT
Utility
Human anti-VEGFR-2/KDR antibodies
16 Mar 20
The invention relates to antibodies that bind to VEGFR-2.
Dan Lu, Zhenping Zhu
Filed: 6 Oct 15
APP
Utility
Treatment of Inflammatory Conditions and Autoimmune Diseases with Glucose Uptake Inhibitors
12 Feb 20
This invention provides methods of treating inflammatory conditions and autoimmune diseases in a mammal, comprising administering to the mammalian subject in need thereof a therapeutically effective amount of a compound, or pro-drug thereof, or pharmaceutically acceptable salt or ester of said compound or pro-drug, wherein the compound is an inhibitor of glucose uptake.
Ji-In Kim, Kellen L. Olszewski, Anthony M. Barsotti, Masha V. Poyurovsky, Kevin G. Liu, Koi Morris, Xuemei Yu
Filed: 26 Apr 18
  • 1
Patents are sorted by USPTO publication date, most recent first